Cover Image
Market Research Report
Product code
1018451

Obesity - Pipeline Insight, 2021

Published: Pre-Order | DelveInsight Business Research LLP | 60 Pages | Delivery time: 2-10 business days

Price

Back to Top
Obesity - Pipeline Insight, 2021
Published: Pre-Order
DelveInsight Business Research LLP
Content info: 60 Pages
Delivery time: 2-10 business days
  • ALL
  • Description
  • Table of Contents
Description

DelveInsight's, "Obesity - Pipeline Insight, 2021," report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in Obesity pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered:

  • Global coverage

Obesity Understanding

Obesity: Overview

A person whose weight is higher than what is considered as a normal weight adjusted for height is described as being overweight or having obesity. Factors that may contribute to weight gain among adults and youth include genes, eating habits, physical inactivity, TV, computer, phone, and other screen time, sleep habits, medical conditions or medications, and where and how people live, including their access to healthy foods and safe places to be active. Overweight and obesity are risk factors for many health problems such as type 2 diabetes, high blood pressure, joint problems, and gallstones, among other conditions.

"Obesity - Pipeline Insight, 2021" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Obesity pipeline landscape is provided which includes the disease overview and Obesity treatment guidelines. The assessment part of the report embraces, in depth Obesity commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Obesity collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights:

  • The companies and academics are working to assess challenges and seek opportunities that could influence Obesity R&D. The therapies under development are focused on novel approaches to treat/improve Obesity.

Obesity Emerging Drugs Chapters

This segment of the Obesity report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Obesity Emerging Drugs

  • Tirzepatide: Eli Lilly and Company

Tirzepatide is a once-weekly dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist that integrates the actions of both incretins into a single novel molecule. GIP is a hormone that may complement the effects of GLP-1 receptor agonists. In preclinical models, GIP has been shown to decrease food intake and increase energy expenditure therefore resulting in weight reductions, and when combined with a GLP-1 receptor agonist, may result in greater effects on glucose and body weight. Tirzepatide is in phase 3 stage of development for the treatment of obesity.

  • Danuglipron: Pfizer

Danuglipron (formerly PF 06882961) is an orally administered, small molecule, glucagon-like peptide 1 receptor (GLP 1R) agonist, being developed by Pfizer. The drug is currently in phase 2 stage of development for the treatment of obesity.

  • Noiiglutide: Jiangsu Hansoh Pharmaceutical

Noiiglutide is a glucagon-like peptide-1 (GLP-1) analogue being developed by Jiangsu Hansoh Pharmaceutical for the treatment of obesity. Currently, it is in phase 2 stage of development.

  • MEDI 0382: MedImmune

MEDI0382 is an oxyntomodulin-like peptide with targeted GLP-1 and glucagon receptor activity. MEDI0382 was discovered and developed in MedImmune's labs and is a dual agonist using natural amino acids. Currently, it is in phase 2 stage of development for the treatment of obesity.

Further product details are provided in the report……..

Obesity: Therapeutic Assessment

This segment of the report provides insights about the different Obesity drugs segregated based on following parameters that define the scope of the report, such as:

  • Major Players in Obesity

There are approx. 50+ key companies which are developing the therapies for Obesity. The companies which have their Obesity drug candidates in the most advanced stage, i.e. phase III include, Eli Lilly and Company.

  • Phases

DelveInsight's report covers around 50+ products under different phases of clinical development like

  • Late stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration

Obesity pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Oral
  • Parenteral
  • Intravenous
  • Subcutaneous
  • Topical.
  • Molecule Type

Products have been categorized under various Molecule types such as

  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Gene therapy
  • Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Obesity: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Obesity therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Obesity drugs.

Obesity Report Insights

  • Obesity Pipeline Analysis
  • Therapeutic Assessment
  • Unmet Needs
  • Impact of Drugs

Obesity Report Assessment

  • Pipeline Product Profiles
  • Therapeutic Assessment
  • Pipeline Assessment
  • Inactive drugs assessment
  • Unmet Needs

Key Questions:

Current Treatment Scenario and Emerging Therapies:

  • How many companies are developing Obesity drugs?
  • How many Obesity drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Obesity?
  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Obesity therapeutics?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Obesity and their status?
  • What are the key designations that have been granted to the emerging drugs?

Key Players

  • Eli Lilly and Company
  • Pfizer
  • Jiangsu Hansoh Pharmaceutical
  • MedImmune
  • Can-Fite Biopharma
  • Novo Nordisk
  • 10xBio
  • Biolingus
  • Shionogi
  • Boehringer Ingelheim
  • Saniona
  • Diasome Pharmaceuticals
  • Empros Pharma
  • Amgen
  • ERX Pharmaceuticals
  • Innovent Biologics
  • Otsuka Pharmaceutical
  • Kyowa Kirin Co., Ltd.
  • Raziel Therapeutics
  • Hanmi Pharmaceutical
  • YSOPIA Biosciences
  • Allysta Pharmaceutical
  • pH Pharma
  • Gannex Pharma
  • Neuraly, Inc.
  • NGM Biopharmaceuticals, Inc
  • Glaceum
  • Carmot Therapeutics
  • LG Chem. Life sciences
  • CohBar
  • Scohia Pharma
  • Click Therapeutics
  • YUHAN
  • UGISense AG
  • Kanion Huawe Pharmaceutical
  • OPKO Health
  • EraCal Therapeutics
  • Kintai Therapeutics
  • NovmetaPharma

Key Products

  • Tirzepatide
  • Danuglipron
  • Noiiglutide
  • MEDI 0382
  • Namodenoson
  • NN 9838
  • Polidocanol
  • BL OPUS I
  • Semaglutide subcutaneous
  • S 237648
  • NNC 01651875
  • Peptide YY
  • BI 456906
  • LY 3305677
  • Tesofensine
  • HDV Biotin
  • BI 1356225
  • EMP16-02
  • AMG 171
  • ERX1000
  • IBI362
  • AMG 133
  • BI 456906
  • NO-13065
  • Bardoxolone methyl
  • RZL-012
  • Efinopegdutide
  • Xla1
  • ALY688-SR
  • PHP-303
  • ASC 41
  • DD01
  • NGM395
  • HSG4112
  • CT-388
  • LR19156
  • LR19020
  • CB4211
  • SCO-272
  • SCO-267
  • SCO-094
  • CT-181
  • YH34160
  • YHC2129
  • YHC2134
  • CT 868
  • Metoprolol/tesofensine
  • OPK-88003
  • KTX-0200
  • NovOB
Table of Contents
Product Code: DIPI1308

Table of Contents

Introduction

Executive Summary

Obesity: Overview

  • Causes
  • Mechanism of Action
  • Signs and Symptoms
  • Diagnosis
  • Disease Management

Pipeline Therapeutics

  • Comparative Analysis

Therapeutic Assessment

  • Assessment by Product Type
  • Assessment by Stage and Product Type
  • Assessment by Route of Administration
  • Assessment by Stage and Route of Administration
  • Assessment by Molecule Type
  • Assessment by Stage and Molecule Type

Obesity - DelveInsight's Analytical Perspective

In-depth Commercial Assessment

  • Obesity companies' collaborations, Licensing, Acquisition -Deal Value Trends

Obesity Collaboration Deals

  • Company-Company Collaborations (Licensing / Partnering) Analysis
  • Company-University Collaborations (Licensing / Partnering) Analysis

Late Stage Products (Phase III)

  • Comparative Analysis

Tirzepatide: Eli Lilly and Company

  • Product Description
  • Research and Development
  • Product Development Activities

Drug profiles in the detailed report…..

Mid Stage Products (Phase II)

  • Comparative Analysis

Danuglipron: Pfizer

  • Product Description
  • Research and Development
  • Product Development Activities

Drug profiles in the detailed report…..

Early Stage Products (Phase I)

  • Comparative Analysis

ERX1000: ERX Pharmaceuticals

  • Product Description
  • Research and Development
  • Product Development Activities

Drug profiles in the detailed report…..

Inactive Products

  • Comparative Analysis

Obesity Key Companies

Obesity Key Products

Obesity- Unmet Needs

Obesity- Market Drivers and Barriers

Obesity- Future Perspectives and Conclusion

Obesity Analyst Views

Obesity Key Companies

Appendix

List of Tables

  • Table 1 Total Products for Obesity
  • Table 2 Late Stage Products
  • Table 3 Mid Stage Products
  • Table 4 Early Stage Products
  • Table 5 Pre-clinical & Discovery Stage Products
  • Table 6 Assessment by Product Type
  • Table 7 Assessment by Stage and Product Type
  • Table 8 Assessment by Route of Administration
  • Table 9 Assessment by Stage and Route of Administration
  • Table 10 Assessment by Molecule Type
  • Table 11 Assessment by Stage and Molecule Type
  • Table 12 Inactive Products

List of Figures

  • Figure 1 Total Products for Obesity
  • Figure 2 Late Stage Products
  • Figure 3 Mid Stage Products
  • Figure 4 Early Stage Products
  • Figure 5 Preclinical and Discovery Stage Products
  • Figure 6 Assessment by Product Type
  • Figure 7 Assessment by Stage and Product Type
  • Figure 8 Assessment by Route of Administration
  • Figure 9 Assessment by Stage and Route of Administration
  • Figure 10 Assessment by Molecule Type
  • Figure 11 Assessment by Stage and Molecule Type
  • Figure 12 Inactive Products